HemaCare Corporation (OTCMKTS:HEMA) Corporate Logo

Change of 3.23% for HEMACARE CORPORATION (OTCMKTS:HEMA)’s short interest was showed. FINRA issued in February HEMA’s total 3,200 short interest. That’s 3.23% up from 3,100 shares. Former HEMA’s position will need 1 days to restore. It has 5,100 average volume.

HEMA touched $12 during the last trading session after $0.5 change.HemaCare Corporation has volume of shares. Since February 14, 2018 HEMA has 0.00% and is . The stock the S&P 500 by 0.00%.

HemaCare Corporation provides human-derived primary blood cells and tissues for biomedical research, and supporting cell therapy clinical trials and commercialization with apheresis collections in the United States.The firm is worth $149.91 million. The firm specializes in the customized collection, isolation, and testing of primary human blood cells and other biological products for research protocols.The P/E ratio is 24.24. The Company’s network of FDA-registered, GMP/GTP-compliant collection centers ensures donor materials available for fresh shipment to customers, as well as for internal use within its isolation laboratory.

For more HemaCare Corporation (OTCMKTS:HEMA) news published recently go to: Seekingalpha.com, Businesswire.com, Business.Financialpost.com, Business.Financialpost.com or Businesswire.com. The titles are as follows: “The New Generex: Unlocking The Value – Seeking Alpha” published on December 18, 2018, “Generex Announces Closing of Acquisition of Controlling Equity Interest in Hema Diagnostic Systems – Business Wire” on January 23, 2017, “Generex Biotechnology Corporation Announces the Filing of a Patent for its New Diagnostic Point-of-Care Platform, the Express II – Financial Post” with a publish date: July 02, 2018, “Generex Announces Closing of First Tranche Acquisition of Operating Assets – Financial Post” and the last “HemaCare to Chair and Present at Phacilitate Leaders World Supply Chain Panel Discussion – Business Wire” with publication date: January 15, 2019.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.